Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug delivery firm Generex Biotechnology Corporation has been granted a US patent relating to a narcotic analgesic formulation delivered by way of a buccal delivery system.
Subscribe to our email newsletter
The formulations covered by the patent are applications of the company’s proprietary RapidMist drug delivery technology and are designed to deliver pain relief medications such as morphine and fentanyl in a convenient alternative to injections and tablets.
Generex’ proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the company’s proprietary RapidMist device.
The RapidMist drug delivery platform, initially applied to insulin with the company’s flagship product, Oral-lyn, can also be applied to small molecule drugs such as morphine and fentanyl, thereby significantly increasing the number of indications for the platform.
“Our mission is to improve drug delivery by making it simpler, more comfortable and more effective, thereby refining and augmenting therapeutic applications and facilitating increased patient compliance,” said Anna Gluskin, president and CEO of Generex.